This New Idea is Set to Shock the World

The $3 AI Biotech Stock That Could Disrupt Drug Discovery—and Reward Investors Big‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

"The convergence of AI and biotech isn't just transforming medicine—it's creating unique opportunities in stocks like ABSI that sit at this intersection." Karim Rahemtulla, Head Fundamental Tactician, Monument Traders Alliance Last week, the market buzzed about Trump's $500 billion Stargate AI project, which aims to revolutionize healthcare by leveraging AI for early cancer detection and custom vaccines. Big names like Oracle, OpenAI, and SoftBank are joining forces, promising groundbreaking advancements in medicine. While this initiative is massive, it highlights a broader trend: artificial intelligence is rapidly reshaping the biotech sector. Companies like Absci Corporation (ABSI) are at the forefront of this shift, using AI to disrupt traditional drug discovery. Unlike the industry giants behind Stargate, ABSI is a speculative microcap—but that's where the opportunity lies. Trading at just $3.78, it's small enough to fly under the radar yet positioned at the intersection of AI and biotech, two high-growth sectors. Let's dive into why ABSI is on our radar and how we're playing it. Why ABSI Could Be a Game-Changer Absci is not your typical biotech. They're combining AI-driven generative models with wet lab technologies to create first-in-class and best-in-class biologics. Their approach could slash the time and cost of drug development—a perfect fit for the AI revolution. Here's what makes ABSI stand out: Big Backers: AMD's $20 Million Investment Earlier this month, AMD invested $20M in Absci through a PIPE deal. This partnership gives ABSI access to AMD's AI chips and computing infrastructure, enabling faster and more efficient R&D. It's a major vote of confidence from one of the biggest players in AI. Promising Drug Pipeline ABSI's pipeline includes three standout candidates: ABS-101 (anti-TL1A antibody for inflammatory bowel disease): Phase 1 trials begin in 1H 2025, with interim data expected in 2H 2025. ABS-201 (antibody for hair loss): Preclinical stage, targeting a massive global market valued at $16 billion by 2030. ABS-301 (immuno-oncology candidate): Focused on solid tumors, with efficacy data due in 1H 2025. While these programs are early-stage, the upside potential is enormous if even one succeeds. Potentially Undervalued with Room to Run With a market cap of $435 million, ABSI looks undervalued, especially given its partnerships and pipeline. How We're Playing ABSI What Is the Dark Ticker? A new rule grants a special trading window AFTER the closing bell (between 4 and 4:15 p.m.). This exclusive ticker has already made top OVERNIGHT gains of 113%... 92%... 88%... 105%... even 157%... all OVERNIGHT! Discover the Dark Ticker We're approaching ABSI as a high-risk, high-reward opportunity. This isn't a blue-chip stock—it's a speculative microcap, so position sizing and allocation discipline are critical. The Trade Strategy We're selling puts to either own ABSI shares at a lower cost or collect premium if the trade doesn't get assigned. Why Sell Puts? Selling puts allows us to take advantage of the stock's volatility while controlling our risk. If assigned, we'll own ABSI shares at a significantly lower price, giving us a favorable cost basis. Otherwise, we'll pocket the premium and move on to the next trade. Key Rule: Only sell puts if you're comfortable owning the shares at your adjusted cost. This is speculative, and biotech microcaps are not for the faint of heart. Risks to Consider This is a speculative trade, and there are significant risks: Early-Stage Pipeline: ABSI's programs are mostly preclinical, with no guarantees of success. Volatility: Microcap stocks like ABSI can experience wild price swings. Cash Burn: While the AMD investment extends ABSI's runway, it's still burning cash at a high rate. Sector Sentiment: Biotech stocks are often highly sensitive to news, both good and bad. Your Action Plan ABSI represents a speculative opportunity with massive upside potential. The AI revolution in biotech is real, and companies like ABSI are poised to lead the charge. With AMD's backing, a promising drug pipeline, and a cheap valuation, ABSI has all the ingredients for a big move. But let me be clear: This is not a trade to go all-in on. Proper allocation and risk management are absolutely essential here. Biotech microcaps are volatile, and ABSI is no exception. If you're ready to play, position size accordingly, and only trade what you're willing to lose. I established a position in ABSI earlier this week. I'm not sharing the strike price or expiration here, but Catalyst Cashouts Live subscribers already know the details. This isn't a "buy and hope" trade—it's a strategic setup designed to limit downside while taking advantage of the upside potential. But timing and execution are critical. If you want to know exactly how I'm positioning myself for this trade—and others like it—Catalyst Cashouts Live is where you need to be. Click here to discover how Catalyst Cashouts Live can help you uncover explosive opportunities just like this. The Dark Ticker Make ONE Simple Trade... On ONE Special Ticker... Within 15 Minutes AFTER Closing Bell... Target 157% The Very Next Morning! Monument Traders Alliance   You are receiving this email because you subscribed to Trade of the Day Wake-Up Watchlist. To unsubscribe from Trade of the Day Wake-Up Watchlist, click here. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Trade of the Day | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 1.800.507.1399 | International: +1.443.353.4977 Website | Privacy Policy Keep the emails you value from falling into your spam folder. Whitelist Trade of the Day. © 2025 Monument Traders Alliance, LLC | All Rights Reserved Nothing published by Monument Traders Alliance should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by Monument Traders Alliance should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Monument Traders Alliance, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.